Treatment of arterial hypertension in patients with diabetes mellitus and nephropathy: current potentialities of renin-angiotensin-aldosterone system block
https://doi.org/10.18705/1607-419X-2003-9-6-191-195
Abstract
Diabetes mellitus and arterial hypertension are major risk factors of cardiovascular complications. Diabetic nephropathy is the most common cause of end-stage chronic renal failure in the world; next is hypertensive nephropathy. Microalbuminuria is the earliest clinical marker of renal dysfunction. The basic clinical significance of microalbuminuria is that it is an independent risk factor of both end-stage chronic renal failure and cardiovascular complications. Controlling blood pressure with antihypertensive agents in patients with diabetes mellitus ensures diminished microalbuminuria and retards the development of chronic renal failure. Angiotensin II receptor blockers and angiotensin-converting enzyme (ACE) inhibitors are essential drugs for the treatment of patients with diabetes mellitus and nephropathy. A combination of these two classes of drugs offers new prospects for nephroprotection in this group of patients.
About the Authors
O. D. Ostroumova
Первый московский государственный медицинский университет имени И.М. Сеченова
Russian Federation
Russian Federation
A. A. Zykova
МГМСУ; ММА им. И.М.Сеченова
Russian Federation
Russian Federation
A. M. Batutina
МГМСУ; ММА им. И.М.Сеченова
Russian Federation
Russian Federation
References
1. King H., Auberg W. H. Diabetes Care 1998; 21: I414-31.
2. Fagan Т.С., Sowers J. Arch Intern Med 1999: 159: 1033-4.
3. Hypertension in Diabetes Study (HDS). J Hypetlens 1999; 11 (3): 319 25.
4. Sawicki P.T., Muhibauer I., Berger M. Diabetologia 1997: 40 (suppl. 2): S134 - 7.
5. UK Prospective Diabetes study Group. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes:UKPDS 38 BMJ 1998: 317: 703-13.
6. Hansson L., Zancbetti A. Carrutbers S.C. Lamcet 1998: 351: 837 – 53.
7. Black H.R., Curh J.D., Pressel S. et al. Hypertension 1991; 17 (suppl. II): II – I – 171.
8. UK Prospective Diabetes Study (UKDPS) Group. Lancet 1998: 352: 837 – 53.
9. Porush J.M., Faubert P.F. Hypertension, diabetes mellitus and nephropathy Sience Preess, London, 2001: p. 9-12.
10. Luft F.C., Agrawal B.J Cardiovasc Pharmacol 1999; 33 (suppl. 1): S11-5.
11. Wang S.I., Head J., Stevens L.,Fuller G.H. Diabetes Care 1996: l9 (4): 305-12.
12. The MRFII research group. JAMA 1982; 248: 1465 - 77.
13. European Society of hypertension - european Society'of cardiology Guidelines for the management arterial hypertension. J Hypertension 2003; 21: 1011 – 53.
14. Jacobsen P., Andersen S., Jensen B.R., Parving H.J. Am Soc Nephrol 2003; 14: 992-9.
Review
For citations:
Ostroumova O.D., Zykova A.A., Batutina A.M. Treatment of arterial hypertension in patients with diabetes mellitus and nephropathy: current potentialities of renin-angiotensin-aldosterone system block. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2003;9(6):191-195. (In Russ.) https://doi.org/10.18705/1607-419X-2003-9-6-191-195
Views:
1936
Email this article 